2024 - Promising Pathways of Blood Biomarkers: Real-World Impact of Bio-Hermes Study

Webinar Preview
Discover an informative webinar in which the first results from the Bio-Hermes-001 study are discussed.
The Bio-Hermes study compared the results of blood and digital biomarkers with brain amyloid PET scans or cerebrospinal fluid assays. It revealed a strong correlation between several blood tests, particularly p-tau 217, with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer’s disease.
In this webinar, experts in the field will discuss what the impact is for people who are living with the disease now and in the near future, in addition to implications for Physicians and Researchers in the field. They will also focus on how the Bio-Hermes study will help in the diagnosis of Alzheimer’s disease and improve clinical trial enrollment.
Register for this webinar today to gain insights about the Bio-Hermes-001 study and the correlation between blood biomarkers and the presence of amyloid plaques in Alzheimer’s disease.
Keywords: Alzheimer's, Alzheimer's Disease, Drug Development, Clinical Research, Amyloid Beta, Biomarkers, Therapeutic Areas, Tau, CNS, Neurology, Basic Research, Neurogenerative Disease